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Abstract
Background Human epidermal growth factor receptor 2 (ERBB2) mutation is a known oncogenic driver mutation in a small
proportion of non-small cell lung cancers (NSCLCs). Many targeted therapies are being developed and investigated for the
treatment of ERBB2-mutated NSCLC, however none of these agents have yet been approved as a front-line treatment. Thus,
platinum-based chemotherapy with or without immunotherapy remains the preferred first-line therapy for ERBB2-mutated
NSCLC.
Objective We aimed to study the activity of chemotherapy in combination with pembrolizumab as first-line treatment in
patients with stage IV ERBB2-mutated NSCLC.
Patients and Methods We retrospectively identified five patients with ERBB2-mutated NSCLC treated with carboplatin,
pemetrexed and pembrolizumab as first-line therapy between 2018 and 2020. Overall survival (OS), progression-free survival
(PFS), and time to next therapy (TTNT) were summarized by Kaplan–Meier methodology using R 4.0.5 with median time
to event. Response rates defined by partial response (PR) or PR + stable disease (SD) and 95% Clopper–Pearson confidence
interval (CI) were calculated.
Results The median age of these five patients was 60 years and all five patients’ tumors had ERBB2 mutations—4 had exon
20 mutation and 1 had exon 23 mutation. With a median follow-up of 32 months, the median OS was 24 months, the median
PFS was 9 months, and the median TTNT was 9 months. The response rate was 0.6 for PR (Clopper–Pearson exact 95% CI
0.147–0.947) and 0.8 for PR and SD (Clopper–Pearson exact 95% CI 0.284–0.995). No unexpected toxicities were observed.
Conclusion In a small number of patients, chemotherapy and pembrolizumab as first-line therapy in ERBB2-mutated NSCLC
patients demonstrated activity similar to previous reports with this regimen. Future clinical trials are needed to determine
the role of chemotherapy and immunotherapy for this patient population in the context of emerging targeted agents.

Key Points
Chemotherapy and immunotherapy remain the preferred
first-line therapy for patients with non-small cell lung
cancer (NSCLC) lacking any actionable mutation.
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There are no approved targeted therapies in the first-line
setting for ERBB2-mutated NSCLC, and there is paucity
of data regarding the efficacy of pembrolizumab and
chemotherapy in this patient population.
Our study showed that the activity of first-line chemotherapy and pembrolizumab in patients with ERBB2mutated NSCLC was similar to previous reports with
this regimen.
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1 Introduction
Lung cancer is the most common cancer worldwide and
is one of the leading causes of cancer-related deaths [1].
Management of advanced stage IV non-small cell lung
cancer (NSCLC) depends largely on several tumor characteristics such as histologic subtype, molecular alterations
and programmed death-ligand 1 (PD-L1) status. Targeted
therapies have been approved in the front-line setting for
stage IV NSCLCs that have driver (i.e. targetable) genetic
alterations such as EGFR mutation and ALK translocation
[2]. Other genetic alterations in NSCLC, such as human
epidermal growth factor receptor 2 (ERBB2) sequence
variants, have been identified and constitute promising
targets for the development of directed therapies [3].
ERBB2 is a member of the ErbB receptor tyrosine
kinase family, which also includes EGFR, HER3, and
HER4. It is encoded by the ERBB2 gene on the long
arm of chromosome 17 (17q12). Alterations of ERBB2
can occur in three ways: amplification, overexpression,
and mutation [4]. The predominant ERBB2 alteration in
NSCLC is mutations in the ERBB2 gene, specifically in
exon 20 [3].
Many targeted therapies are currently being developed
or have been evaluated for ERBB2-positive NSCLC,
including antibody drug conjugates (ADCs) such as adotrastuzumab emtansine (T-DM1) and trastuzumab deruxtecan, and small-molecule tyrosine kinase inhibitors (TKIs)
such as lapatinib and afatinib, which are dual EGFR/
ERBB2 inhibitors, and dacomitinib, neratinib, poziotinib,
and pyrotinib, which are irreversible pan-ErbB receptor
inhibitors [3].
Over the last few years, the preferred front-line therapy
in advanced NSCLC patients without targetable alteration
is the combination of chemotherapy and immunotherapy.
There is paucity of data regarding the activity of chemotherapy and immunotherapy in ERBB2-mutated NSCLC
patients, therefore we conducted a retrospective review of
ERBB2-mutated NSCLC patients treated with a combination of chemotherapy and pembrolizumab as front-line
therapy.

2 Methods
We retrospectively identified five patients who had
ERBB2-mutated NSCLC by reviewing the charts of
patients with stage IV NSCLC treated at two cancer centers between 2018 and 2020. All patients in this series were
treated with a combination of carboplatin, pemetrexed, and
pembrolizumab as front-line therapy. All patients were
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evaluated and treated between 2018 and 2020 at two cancer centers in the US. ERBB2 mutations were detected
using next-generation sequencing (NGS) assays of the
tumor tissue obtained at diagnosis (in-house assay in four
patients and a commercial NGS assay in one patient).
Overall survival (OS) was defined as the length of time
from the start of first-line treatment to the date of death or
the date of last contact; progression-free survival (PFS)
was defined as the length of time from the start of firstline treatment to the date of progression (PD) or death as
defined by the treating physician; and time to next therapy
(TTNT) was defined as the length of time between the start
of first-line treatment to the start of second-line treatment
or death. Response rate (RR) was defined as the rate of
partial response (PR) and/or stable disease (SD) achieved
after two to three cycles of chemotherapy and pembrolizumab; response was rated per the Response Evaluation
Criteria in Solid Tumors (RECIST) 1.1 criteria. Patients
had imaging studies at least every 12 weeks, with shorter
intervals during the initial four to six cycles. OS, PFS, and
TTNT were summarized by Kaplan–Meier methodology
using R 4.0.5 with median time to event. RRs summarized
by PR or PR + SD and 95% Clopper–Pearson confidence
interval (CI) were calculated.

3 Results
The median age of the five patients was 60 years. Three
patients never smoked cigarettes and two patients had a
smoking history (20 and 25 pack-years). PD-L1 tumor proportion score (TPS) was 5% in two patients and < 1% in
three patients. Four patients had bone metastases and three
patients had brain metastases at diagnosis. All five patients’
tumors had ERBB2 mutations—4 had exon 20 mutation and
1 had exon 23 mutation (Table 1).
The median number of chemotherapy and immunotherapy cycles received (including maintenance pemetrexed and
pembrolizumab) was 14 cycles (range 2–20), the median
number of pembrolizumab cycles was 14 (range 2–26), and
the median number of maintenance chemotherapy cycles
(with pembrolizumab) was 10 (range 3–15).
With a median follow-up of 32 months, the median
OS was 24 months, 1-year survival probability was 0.750
(95% CI 0.426–1), and 2-year survival probability was
0.375 (95% CI 0.084–1) (Fig. 1). The median PFS was 9
months, 1-year progression probability was 0.40 (95% CI
0.137–1), and 2-year progression probability was 0.2 (95%
CI 0.035–1) (Fig. 2). The median TTNT was 9 months and
the 1-year TTNT probability after first-line therapy was
0.40 (95% CI 0.137–1) (Fig. 3). PR was achieved in three
of five patients with an RR of 0.6 (Clopper–Pearson exact
95% CI 0.147–0.947), and four of five patients achieved PR
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Table 1  Patient characteristics
Characteristic
Median age, years
Sex
Male
Female
Smoking
Never smokers
Limited smoking
ECOG performance status
0
1
PD-L1 TPS
5%
< 1%
Metastases at diagnosis
Bone
Brain
ERBB2 mutation
Exon 20
Exon 23

60
2
3
3
2
2
3
2
3
4
3
4
1

Fig. 2  Progression-free survival for patients with ERBB2-mutated
non-small cell lung cancer treated with chemotherapy and immunotherapy

ECOG Eastern Cooperative Oncology Group, PD-L1 programmed
death-ligand 1, TPS tumor proportion score

Fig. 1  Overall survival for patients with ERBB2-mutated non-small
cell lung cancer treated with chemotherapy and immunotherapy

and SD with an RR of 0.8 (Clopper–Pearson exact 95% CI
0.284–0.995).
Treatment-related adverse events were collected retrospectively from patients’ charts. The most common adverse

Fig. 3  TTNT for patients with ERBB2-mutated non-small cell lung
cancer treated with chemotherapy and immunotherapy. TTNT time to
next therapy

events of the studied regimen were nausea and vomiting,
fatigue (100%), watery eyes (60%), and cytopenia (40%). All
adverse events were grade 1–2. Regarding immunotherapyrelated adverse events, one patient had hypothyroidism that
was managed with thyroid hormone replacement and another
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patient had fever following pembrolizumab infusion that was
managed with corticosteroids after treatment. Other adverse
events that were possibly related to immunotherapy were
diarrhea and arthritis in two patients, however they were
grade 1 and did not require any treatment.
Of the three patients who progressed on chemotherapy
and pembrolizumab, two were treated with docetaxel and
ramucirumab as subsequent therapy and one patient was
started on an investigational ERBB2-directed agent. Two
patients received fam-trastuzumab deruxtecan as third-line
therapy and one patient received ado-trastuzumab emtansine. Only one patient received an ERBB2-directed TKI
(poziotinib).

4 Discussion
Very limited data are available on the efficacy of the combination of chemotherapy and immunotherapy in patients
with ERBB2-mutated NSCLC. We report the results of five
patients with ERBB2-mutated NSCLC treated with carboplatin/pemetrexed and pembrolizumab as first-line therapy.
The median OS in these patients was 24 months, PFS was
9 months, and TTNT was 9 months.
We assessed TTNT, in addition to PFS, as this was a
retrospective review of patients managed by different physicians with different disease assessment schedules. This
endpoint has been considered as a measure of efficacy by
other investigators.
Approximately 2–4% of patients with NSCLC carry
ERBB2 sequence variants, which are most commonly found
in women, individuals of Asian ethnicity, those with no history of smoking, and in adenocarcinomas [5]. ERBB2-positive NSCLC has the tendency to metastasize to the lungs and
bones [5]. The most common ERBB2 variants are insertions
or duplications of the amino acids tyrosine, valine, methionine, and alanine (YVMA) at codon 776 (YVMA 776–779
ins) in exon 20, accounting for 80–90% of all ERBB2 variations [6]. With greater use of NGS to detect all the relevant
genetic alterations in NSCLCs, there is an expectation that
ERBB2 mutations in NSCLC will be detected more frequently [6]. While ERBB2 sequence variations are thought
to not occur with other driver genetic alterations, such as in
ALK and EGFR, the European EUHER2 cohort has reported
concomitant alterations in EGFR, ALK, and ROS1 in five
patients [7].
The effect of ERBB2 variant status on the response to
chemotherapy is controversial. Wang et al. [8] showed inferior outcomes in patients with ERBB2 allelic alterations who
received first-line treatment with pemetrexed, and platinum
chemotherapy, compared with patients with ALK and ROS1
rearrangements or EGFR sequence variations. On the contrary, Li et al. [9] reported better outcomes in patients with
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ERBB2 alterations who received pemetrexed and platinum
chemotherapy. Mazières et al. identified 101 patients with
ERBB2-positive NSCLC who had an overall RR (ORR) of
43.5% and a median PFS of 6 months with conventional
first-line chemotherapy [7].
Targeted therapies are being extensively studied in
ERBB2-mutated NSCLC, with some showing promising results. Trastuzumab-emtansine (T-DM1), an ADC
targeted against ERBB2, showed a PFS of 5 months in a
phase II basket trial [10]. Its efficacy was confirmed in a
subsequent phase II trial reporting an ORR of 44% in the
same patient population [11]. Fam-trastuzumab deruxtecannxki (T-Dxd), another ADC against ERBB2, was granted
a breakthrough designation by the US FDA based on the
results of the Destiny-Lung01 trial. The study reported an
ORR of 55%, median PFS of 8.2 months, and median OS of
17.8 months in ERBB2-mutated NSCLC patients previously
treated with platinum chemotherapy [12]. Small-molecule
TKIs were also effective in the treatment of ERBB2-mutated
NSCLC and have shown an ORR ranging from 3.8% to
approximately 40%. Gastrointestinal adverse effects can be
the major dose-limiting toxicities with these TKIs [13].
Evidence of the impact of ERBB2 alterations on the
response to immune checkpoint inhibitors (ICIs) as a single agent or in combination with chemotherapy is limited.
Mazieres et al. reported 29 patients with ERBB2-positive
NSCLC who had received single-agent ICIs. The PFS for
these patients was 2.5 months and was positively associated
with smoking status, whereas the OS was 20.3 months and
did not correlate with smoking status or PD-L1 level [14].
Guisier et al. reported on 23 patients with activating ERBB2
sequence variations who received ICIs after progressing on
first-line treatment. The median PFS was 2.2 months (range
1.7–15.2) and the median OS was 20.4 months (range
9.3–not reached) [15]. Patil et al. reported a significantly
prolonged PFS in patients with ERBB2 allelic variations
(10 within exon 20 and 1 within exon 19) and patients with
atypical EGFR mutations who received ICIs with platinum
doublet chemotherapy relative to those who received ICIs as
monotherapy (7 vs. 2 months; p < 0.001; hazard ratio 0.06,
95% CI 0.01–0.53) [5].
In our study, five patients with ERBB2 sequence variations (exon 20 in four patients and exon 23 in one patient)
were treated with carboplatin, pemetrexed and pembrolizumab as first-line therapy. The median TTNT of 9 months,
median PFS of 9 months, and median OS of 24 months are
consistent with the results reported with this therapy in nonsquamous NSCLC patients in the Keynote 189 trial [16]. The
three patients who required the next line of therapy went on
to receive HER2-directed therapy. PR was achieved in three
of five patients after two to three cycles of chemotherapy
and pembrolizumab, and SD was achieved in one patient.
No unexpected adverse events were observed in these
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patients. It is not clear if the addition of pembrolizumab to
chemotherapy provides superior outcomes in all molecularly
defined subsets of NSCLC. Previous retrospective reviews
suggest that in ERBB2-mutated NSCLC patients, front-line
chemotherapy demonstrates a median PFS of 6 months [7,
8]. Further studies will need to be conducted to assess if the
addition of pembrolizumab to platinum-based chemotherapy
provides superior outcomes in ERBB2-mutated NSCLC.
The are several limitations to our study. First, this was
a retrospective analysis and included a small number of
patients. In addition, TTNT is not a commonly utilized efficacy criterion. Finally, adverse events may not be recorded
as diligently as in clinical trial patients. Very limited data are
available regarding the efficacy of chemotherapy and immunotherapy as front-line therapy in ERBB2-mutated NSCLC
patients; therefore, despite the limitations of a retrospective
analysis, the results in these five patients provides information regarding the outcomes of ERBB2-mutated NSCLC
treated with chemotherapy and immunotherapy as first-line
therapy.

5 Conclusion
NSCLCs harboring sequence variations in ERBB2 constitute a specific entity of lung cancer with driver mutations.
The role of chemotherapy and immunotherapy as first-line
therapy for this specific subset of NSCLC patients remains
to be defined. Due to the lack of targeted therapy options in
the front-line setting, chemotherapy with pembrolizumab
should be considered for first-line therapy in stage IV
ERBB2-altered NSCLC. However, it remains to be determined whether the addition of pembrolizumab to platinumbased chemotherapy provides any additional benefit in this
patient population. Our results warrant further study of
chemotherapy and immunotherapy as first-line therapy in
ERBB2-mutated NSCLC patients.
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